• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Sage Therapeutics

Quote
anonymous said:
My apology board monitor. Payers will cover ambulatory pump over hospitalization. This product is a game changer for women with PPD.
Click to expand...

This post sounds like planted PR. Payers are unlikely to approve an ambulatory pump without a fight. Doesn’t look like there’ll be any reimbursement specialists on board. Good luck, everyone.
 




anonymous said:
Why?

Why must Cafepharma posts, on any board - not just Sage’s - always devolve into a immature, school yard pissing match between posters? I don’t get it. What has happened to civility and professional courtesy/respect? Must everything come down to, “Nee ner, nee ner. I’m so insecure that I need to pass myself off as having one more speck of information you don’t. So there... (picture thumbs in ears, waving fingers with tongue sticking out). Seriously...

Hiring events for the field, I was told, are still a month and half away. Training October. Main recruiter is Taylor Strategy Partners. If this molecule is a “game-changer”, then delivery may not matter as mngd care will adjust. Managed Care teams at Sage I’m sure will be working P&T committee’s between now and October utilization meetings so 2019 formularies will hopefully reflect 217’s acceptance. PDUFA isn’t until December 19th. You may want to bone up on the GABA/Glutamate neuronal pathway relationship.

Best of luck
Click to expand...
P&T committee’s aren’t going to waste a minute of their time ‘deciding’ on a product that may or may not get FDA approval. Their timeline on decision starts WHEN FDA approves 217
 








Can anyone comment on the study results? Placebo scores looked pretty close to drug.

P&T committee’s aren’t going to waste a minute of their time ‘deciding’ on a product that may or may not get FDA approval. Their timeline on decision starts WHEN FDA approves 217

This post sounds like planted PR. Payers are unlikely to approve an ambulatory pump without a fight. Doesn’t look like there’ll be any reimbursement specialists on board. Good luck, everyone.

Some of the leadership is AWFUL and if you are interviewing for those areas, definitely run for the hills.

Payers will cover ambulatory pump over hospitalization. This product is a game changer for women with PPD.
Probably only getting interviews from RBD if you have a referral

Research is wrong. 2.5 days, and can be done with an outpatient infusion pump. If you don't understand that, you're already out of your league on this one.

yes 60 hour infusion. It will be a tough sell

Seems like the "First in Class" product is the PR from the company. It appears they want CNS rep but don't want to pay.
The skill set need for this product is being downplayed for cheap labor. IMHO.

Research says 3 day hospital in-patient infusion. Not many payers will cover. PA will be brutal

Run for the hills!

Seems like you all have it figured out. I guess I don't need to continue the interview process, talk to the hiring manager, meet any leadership, see any actual results, discuss an offer, assess managed care in my area, consider the pipeline and future molecules, find out who the Account Manager for this area is, discuss with local physicians their perceptions of 217, or, and I know this will really confound some of you, discuss with my family whether this may be the right move for us irrespective of simply looking at pay.

Thanks for all the great information.

 




anonymous said:
This post sounds like planted PR. Payers are unlikely to approve an ambulatory pump without a fight. Doesn’t look like there’ll be any reimbursement specialists on board. Good luck, everyone.
Click to expand...

Tell that to Biogen and their MS franchise you moron. Sounds like you are too uninformed to get any job, let alone a sales post.
 
































anonymous said:
Word is a lot of these positions are going to be filled with RBD referrals. Unless it’s a hard to fill geography, you have to know someone to get these gigs.
Click to expand...

Interesting. If true, then Sage is no different than a lot of other pharma companies. Nepotism is alive and well!
This seems to contradict the culture pr campaign Sage is running telling me how different they are.

Let’s hope the “word” isn’t true
 




anonymous said:
Interesting. If true, then Sage is no different than a lot of other pharma companies. Nepotism is alive and well!
This seems to contradict the culture pr campaign Sage is running telling me how different they are.

Let’s hope the “word” isn’t true
Click to expand...

Highly unlikely anyone on CP is connected, just disgruntled.
 
















From what I’ve seen they are interviewing in one region at a time. And good luck trying to get a taylor’s Recruiter to respond to you at all. I haven’t seen anyone recruiting in Texas yet.
 












Top Bottom
Back
Quote